| abstract |
A compound of formula (Ia), (Ib) or (Ic) or pharmaceutically acceptable salts thereof wherein in formula (Ia) A is a phenyl or six-membered heteroaryl having 1-3 N atoms wherein the phenyl or heteroaryl may be optionally substituted; B is selected from H, D, F, hydroxyl, propyn-1-yl, C1-3alkyl, hydroxyC1-3alkoxy, C1-3alkoxy, C1-3alkyl-O-C1-3alkyl, CONR1R2, C1-3alkylCONR1R2, C3-6cycloalkyl, a 4-6 membered heterocyclyl or a 5-6 membered heteroaryl; R1 and R2 are each independently a substituent or NR1R2 together form a 4-7 membered heterocyclic ring; X is O, CH2, N or S; Y is a linker group as herein described; R9 and R10 are independently hydrogen, halo, optionally substituted C1-2alkyl, C1-3alkoxy or hydroxyl or R9 and R10 together form an azabicyclo[3.3.1]nonane, a 3-oxa-7-azabicyclo[3.3.1]nonane or an azabicyclo[3.2.1]octane; R11 is hydrogen, halo, optionally substituted C1-2alkyl or C1-3alkoxy; p and q are each 0, 1 or 2 provided that 0 ¤p+q ¤2 and Z is -C(O)OR4, -C(O)R4, -S(O)2R4, -S(O)2N(C1-3alkyl)R4, phenyl, benzyl, heteroaryl or -CH2-heteroaryl any of which may be optionally substituted and R4 is a substitutent; in formula (Ib) V is a bond, CMe2, a spiroC3-6cycloalkyl or a spiro 4-6 membered heterocycle; W is CH2 or VW together form a C3-6cycloalkyl or a 5-6 membered heterocyclyl and moieties A,B,X,Y,Z,R9,R10,R11,p and q are as defined for formula (Ia); In formula (Ic) E is O, NR8 or S; R3 is hydrogen, fluorine, or propyn-1-yl; R8 is hydrogen, methyl, ethyl, n-propyl or i-propyl; R5, R6 and R7 are independently selected from hydrogen or halo and moieties A,B,X,Y,Z,R9,R10,R11,p and q are as defined for formula (Ia). Compounds of formula (Ia), (Ib) and (Ic) are useful as agonists of GPR119 and GPR40 receptors in the treatment of type II diabetes. |